Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000899243-22-004200
Filing Date
2022-02-02
Accepted
2022-02-02 18:00:37
Documents
1
Period of Report
2022-02-01

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 5902
  Complete submission text file 0000899243-22-004200.txt   7312
Mailing Address 201 E. JEFFERSON ST., SUITE 110B LOUISVILLE KY 40202
Business Address 201 E. JEFFERSON ST., SUITE 110B LOUISVILLE KY 40202 502-569-1059
Talaris Therapeutics, Inc. (Issuer) CIK: 0001827506 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O TALARIS THERAPEUTICS, INC. 93 WORCESTER STREET, SUITE 120 WELLESLEY MA 02481
Business Address
Zdanowski Michael (Reporting) CIK: 0001845662 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40384 | Film No.: 22585181